Dara-Rd or Dara-VRd: When Deeper Response Meets a Frailty Question
Adding a fourth drug to her induction regimen might get her deeper into remission faster. Whether she can tolerate what that fourth drug does to her hands and feet is a separate question the response-rate data doesn't answer.
Eleanor F. still tends the same vegetable garden she and her late husband put in together decades ago, refusing every offer to hire someone or scale it back — forty tomato plants this year, she says, same as always. She is 79, spent forty years working as a nurse before retiring, and was diagnosed with IgG kappa multiple myeloma after presenting with worsening back pain and fatigue she'd initially attributed to a hard planting season and her age in roughly equal parts.
Imaging confirmed multiple lytic bone lesions and labs showed a hemoglobin of 8.6 — disease burden significant enough that the team wants meaningful, timely disease control, not a slow-building response. Mild chronic kidney disease, with a creatinine of 1.4, and a borderline frailty profile placed her in the transplant-ineligible category at her staging conference, a designation that shapes which induction regimens are even on the table before efficacy is weighed at all. Her functional status otherwise remains excellent for her age, still managing the garden's full workload without help.
Daratumumab-lenalidomide-dexamethasone, established by the MAIA trial specifically in transplant-ineligible newly diagnosed myeloma, is a direct population match for her situation — MAIA enrolled patients who look like her, not a fitter population she'd be extrapolated into. Adding bortezomib to build a quadruplet regimen carries real promise for a deeper response, but also carries bortezomib's own defining toxicity, peripheral neuropathy, in a woman whose stated goal is staying independent in the house she and her husband shared — walking, cooking, managing her own medications — not just achieving the deepest number on a response-depth chart.
Choosing induction intensity before the frailty score is in hand
Given her disease burden — lytic lesions, hemoglobin under 9 — I'd lean toward quadruplet dara-VRd for the deepest and fastest possible response. CEPHEUS (Usmani et al., 2025) tested exactly that quadruplet, daratumumab added to VRd, in transplant-ineligible and transplant-deferred patients, and it raised MRD-negativity from 39% to 61% with a 43% reduction in the risk of progression or death.
MAIA specifically enrolled transplant-ineligible patients — that's not an extrapolation for her, that's a direct population match, and dara-Rd's long-term data in exactly her situation is well established. Adding bortezomib means adding real neuropathy risk in a frail 79-year-old whose entire goal is staying independent in her own home. And read CEPHEUS's entry criteria before you apply it to her: it enrolled patients under 80 with an IMWG frailty score of 0 or 1 — fit or intermediate-fit, frail patients excluded by design. She is 79, which clears the age bar by a year, and nobody in this room has actually scored her frailty. If she scores frail, the trial you are quoting deliberately did not enroll her.
MRD-negativity is a real, meaningful surrogate — I won't argue otherwise.
But neither of you is actually disagreeing about the surrogate. You're disagreeing about how much toxicity a patient with her specific frailty profile can absorb to reach it, and you're both reasoning from proxies — disease burden on one side, age and general frailty impression on the other — rather than from an actual measurement. Score her formally with the IMWG frailty index before finalizing this. If she scores frail, dara-Rd is the clear choice. If she scores intermediate-fit, a dose- or frequency-modified bortezomib-containing regimen becomes a reasonable middle path neither of your current positions is describing.
Agreed: formally score her IMWG frailty index before finalizing the regimen. If frail, proceed with dara-Rd per MAIA; if intermediate-fit, add bortezomib at a reduced, neuropathy-mitigating frequency.
Not fully resolved: exactly which modified bortezomib schedule would apply if she scores intermediate-fit — left for that scenario specifically, since the team did not want to commit to a dosing schedule for a category she may not end up in.